Phibro Animal Health Corporation (PAHC)
USD 17.45
(-1.52%)
USD 17.45
(-1.52%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 260.29 Million USD | 14.98% |
| 2023 | 226.39 Million USD | 9.69% |
| 2022 | 206.4 Million USD | 5.04% |
| 2021 | 196.5 Million USD | 4.69% |
| 2020 | 187.7 Million USD | 3.47% |
| 2019 | 181.4 Million USD | 7.98% |
| 2018 | 168 Million USD | 11.78% |
| 2017 | 150.3 Million USD | -1.96% |
| 2016 | 153.3 Million USD | 3.09% |
| 2015 | 148.7 Million USD | 3.27% |
| 2014 | 144 Million USD | 17.81% |
| 2013 | 122.23 Million USD | 6.46% |
| 2012 | 114.81 Million USD | 8.9% |
| 2011 | 105.42 Million USD | 3.46% |
| 2010 | 101.89 Million USD | 15.53% |
| 2009 | 88.19 Million USD | -4.55% |
| 2008 | 92.4 Million USD | 2.44% |
| 2007 | 90.19 Million USD | 32.45% |
| 2006 | 68.09 Million USD | 1.79% |
| 2005 | 66.89 Million USD | 47.03% |
| 2004 | 45.5 Million USD | -28.12% |
| 2003 | 63.29 Million USD | -10.34% |
| 2002 | 70.6 Million USD | 10.49% |
| 2001 | 63.89 Million USD | 10.55% |
| 2000 | 57.79 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 58.68 Million USD | -6.73% |
| 2024 Q4 | 74.14 Million USD | 26.34% |
| 2024 Q2 | 62.91 Million USD | -8.15% |
| 2024 FY | 250.06 Million USD | 10.46% |
| 2024 Q1 | 68.5 Million USD | 29.49% |
| 2023 Q2 | 61.54 Million USD | 11.97% |
| 2023 Q4 | 52.9 Million USD | -7.19% |
| 2023 Q3 | 57 Million USD | -7.38% |
| 2023 FY | 226.39 Million USD | 9.69% |
| 2023 Q1 | 54.96 Million USD | -0.97% |
| 2022 Q2 | 48.37 Million USD | -3.37% |
| 2022 FY | 206.4 Million USD | 5.04% |
| 2022 Q4 | 55.5 Million USD | 5.85% |
| 2022 Q3 | 52.43 Million USD | 8.38% |
| 2022 Q1 | 50.06 Million USD | -1.25% |
| 2021 Q3 | 49.03 Million USD | 1.36% |
| 2021 Q4 | 50.7 Million USD | 3.4% |
| 2021 Q2 | 48.37 Million USD | -0.12% |
| 2021 Q1 | 48.43 Million USD | 14.22% |
| 2021 FY | 196.5 Million USD | 4.69% |
| 2020 Q4 | 42.4 Million USD | -12.09% |
| 2020 FY | 187.7 Million USD | 3.47% |
| 2020 Q1 | 47.51 Million USD | -10.68% |
| 2020 Q2 | 49.49 Million USD | 4.16% |
| 2020 Q3 | 48.23 Million USD | -2.55% |
| 2019 FY | 181.4 Million USD | 7.98% |
| 2019 Q2 | 42.93 Million USD | -0.03% |
| 2019 Q3 | 42.3 Million USD | -1.48% |
| 2019 Q4 | 53.2 Million USD | 25.76% |
| 2019 Q1 | 42.95 Million USD | 3.75% |
| 2018 Q2 | 42.98 Million USD | 4.84% |
| 2018 Q1 | 40.99 Million USD | 3.52% |
| 2018 FY | 168 Million USD | 11.78% |
| 2018 Q4 | 41.4 Million USD | -2.76% |
| 2018 Q3 | 42.57 Million USD | -0.94% |
| 2017 Q3 | 30.64 Million USD | -25.02% |
| 2017 Q1 | 39.18 Million USD | -0.79% |
| 2017 FY | 150.3 Million USD | -1.96% |
| 2017 Q4 | 39.6 Million USD | 29.22% |
| 2017 Q2 | 40.87 Million USD | 4.3% |
| 2016 FY | 153.3 Million USD | 3.09% |
| 2016 Q4 | 39.5 Million USD | 1.85% |
| 2016 Q3 | 38.78 Million USD | -2.54% |
| 2016 Q2 | 39.79 Million USD | 3.9% |
| 2016 Q1 | 38.3 Million USD | -3.97% |
| 2015 Q3 | 37.29 Million USD | 2.75% |
| 2015 FY | 148.7 Million USD | 3.27% |
| 2015 Q2 | 36.29 Million USD | 3.05% |
| 2015 Q4 | 39.88 Million USD | 6.94% |
| 2015 Q1 | 35.22 Million USD | -14.5% |
| 2014 Q2 | 34.13 Million USD | 3.09% |
| 2014 Q4 | 41.2 Million USD | 15.99% |
| 2014 Q1 | 33.11 Million USD | -0.41% |
| 2014 Q3 | 35.52 Million USD | 4.05% |
| 2014 FY | 144 Million USD | 17.81% |
| 2013 Q3 | 31.29 Million USD | 7.8% |
| 2013 Q2 | 29.03 Million USD | 0.06% |
| 2013 Q4 | 33.25 Million USD | 6.25% |
| 2013 Q1 | 29.01 Million USD | 0.0% |
| 2013 FY | 122.23 Million USD | 6.46% |
| 2012 FY | 114.81 Million USD | 8.9% |
| 2011 FY | 105.42 Million USD | 3.46% |
| 2010 Q2 | 25.79 Million USD | 7.05% |
| 2010 Q1 | 24.09 Million USD | -62.28% |
| 2010 FY | 101.89 Million USD | 15.53% |
| 2009 Q4 | 63.89 Million USD | 186.55% |
| 2009 Q3 | 22.29 Million USD | 8.25% |
| 2009 Q2 | 20.59 Million USD | 0.49% |
| 2009 FY | 88.19 Million USD | -4.55% |
| 2009 Q1 | 20.5 Million USD | -1.91% |
| 2008 Q4 | 20.9 Million USD | -35.49% |
| 2008 Q2 | 19.4 Million USD | -1.52% |
| 2008 Q1 | 19.7 Million USD | 2.6% |
| 2008 FY | 92.4 Million USD | 2.44% |
| 2008 Q3 | 32.4 Million USD | 67.01% |
| 2007 FY | 90.19 Million USD | 32.45% |
| 2007 Q4 | 19.2 Million USD | -0.52% |
| 2007 Q2 | 19.79 Million USD | -37.54% |
| 2007 Q1 | 31.7 Million USD | 68.62% |
| 2007 Q3 | 19.3 Million USD | -2.53% |
| 2006 Q2 | 16.79 Million USD | 11.26% |
| 2006 Q3 | 17.59 Million USD | 4.76% |
| 2006 Q4 | 18.79 Million USD | 6.82% |
| 2006 FY | 68.09 Million USD | 1.79% |
| 2006 Q1 | 15.09 Million USD | 0.67% |
| 2005 Q2 | 16.9 Million USD | 6.29% |
| 2005 FY | 66.89 Million USD | 47.03% |
| 2005 Q4 | 15 Million USD | -11.76% |
| 2005 Q1 | 15.89 Million USD | -21.67% |
| 2005 Q3 | 17 Million USD | 0.59% |
| 2004 Q3 | 16.09 Million USD | 340.3% |
| 2004 FY | 45.5 Million USD | -28.12% |
| 2004 Q1 | 15.79 Million USD | 17.04% |
| 2004 Q2 | -6.7 Million USD | -142.41% |
| 2004 Q4 | 20.3 Million USD | 26.09% |
| 2003 Q1 | 15.9 Million USD | 0.0% |
| 2003 Q3 | 17.79 Million USD | 9.88% |
| 2003 Q4 | 13.5 Million USD | -24.16% |
| 2003 FY | 63.29 Million USD | -10.34% |
| 2003 Q2 | 16.2 Million USD | 1.89% |
| 2002 FY | 70.6 Million USD | 10.49% |
| 2001 FY | 63.89 Million USD | 10.55% |
| 2000 FY | 57.79 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -3054.029% |
| Alpha Teknova, Inc. | 45.85 Million USD | -467.605% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -32.817% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -480.323% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -63.496% |
| Cosmos Health Inc. | 26.18 Million USD | -894.233% |
| Journey Medical Corporation | 54.59 Million USD | -376.789% |
| Embecta Corp. | 528.4 Million USD | 50.738% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 4.266% |
| Dynavax Technologies Corporation | 219.14 Million USD | -18.779% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 55.882% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 20.246% |
| PainReform Ltd. | 9.58 Million USD | -2615.964% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1883.303% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1883.303% |
| SCYNEXIS, Inc. | 51.84 Million USD | -402.041% |
| Safety Shot Inc | 12.1 Million USD | -2049.501% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -8381.005% |
| Procaps Group, S.A. | 199.47 Million USD | -30.49% |
| Theratechnologies Inc. | 72.75 Million USD | -257.768% |
| Harrow Health, Inc. | 89.97 Million USD | -189.307% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -2655.643% |
| Biofrontera Inc. | 39.95 Million USD | -551.413% |
| DURECT Corporation | 43.71 Million USD | -495.443% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 50.795% |
| Cronos Group Inc. | 96.7 Million USD | -169.156% |
| OptiNose, Inc. | 85.1 Million USD | -205.866% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -12.137% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -564.823% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2822.498% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 17.138% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -2574.981% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -504.774% |
| Radius Health, Inc. | 265.92 Million USD | 2.117% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1780.507% |
| ProPhase Labs, Inc. | 37.85 Million USD | -587.673% |
| Procaps Group S.A. | 187.24 Million USD | -39.015% |
| Alvotech | 285.43 Million USD | 8.808% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -2549.344% |
| Viatris Inc. | 5.96 Billion USD | 95.637% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1593.105% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -334.99% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1080.863% |
| Tilray Brands, Inc. | 251.35 Million USD | -3.557% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -430.809% |
| Shineco, Inc. | 17.94 Million USD | -1350.287% |
| PetIQ, Inc. | 192.72 Million USD | -35.062% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -6421.899% |
| Incannex Healthcare Limited | 30.05 Million USD | -766.13% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 83.696% |
| Alimera Sciences, Inc. | 62.64 Million USD | -315.539% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -34037.801% |
| Assertio Holdings, Inc. | 368.58 Million USD | 29.379% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -4322.647% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1361.648% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1129.619% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1137.035% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -57.789% |
| Hempacco Co., Inc. | 7.59 Million USD | -3326.575% |
| Talphera, Inc. | 11.99 Million USD | -2070.235% |
| Alvotech | 285.43 Million USD | 8.808% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -84.984% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 24.53% |
| Currenc Group, Inc. | 24 Million USD | -984.481% |
| Kamada Ltd. | 45.42 Million USD | -473.015% |
| Indivior PLC | 911 Million USD | 71.427% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1997.546% |
| Flora Growth Corp. | 10.57 Million USD | -2360.516% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1137.035% |
| Evolus, Inc. | 189.75 Million USD | -37.173% |
| HUTCHMED (China) Limited | 436.23 Million USD | 40.33% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -68.878% |
| Akanda Corp. | 3.48 Million USD | -7372.295% |